Molecular Signature for Breast Cancer Predicts Sensitivity to Radiotherapy

Share this content:

(ChemotherapyAdvisor) – A newly developed molecular signature predicts whether breast cancer patients will be sensitive to radiotherapy, according to an international team of researchers. This conclusion is based on a study entitled “Validation of a Radiosensitivity Molecular Signature in Breast Cancer,” which was published online in Clinical Cancer Research.

The design of this study is based on the prior development of a radiosensitivity molecular signature (RSI), which uses a specific set of breast cancer-associated genes to measure the sensitivity of 2 populations of breast cancer patients to radiotherapy. In this study, the investigators evaluated the same RSI using 2 new populations of breast cancer patients at 2 different medical centers: the Karolinska University Hospital (n=159) and Erasmus Medical Center (n=344).

Using the RSI as an outcome measure, the investigators found that “patients predicted to be radiosensitive (RS) had an improved 5-year relapse-free survival when compared with radioresistant (RR) patients (95% vs. 75%, P = 0.0212).” The investigators also found that the RSI was specific to treatment with radiotherapy as no difference in RSI was found between RS and RS patients treated without radiotherapy (71% vs. 77%, P = 0.6744).

“Similarly, in the Erasmus dataset, radiotherapy-treated RS patients had an improved 5-year distant-metastasis-free survival over RR patients (77% vs. 64%, P = 0.0409), but no difference was observed in patients treated without radiotherapy (P = 0.9425),” the investigators wrote.

The most important observation in this study was that this RSI can predict the outcome of radiotherapy for estrogen receptor-positive breast cancer patients (HR=2.64, P = 0.0085), allowing further personalization of therapy for this population.



Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs